Drug distributor Cencora raised its fiscal 2025 profit forecast on Wednesday, driven by robust demand for expensive specialty medicines.

Cencora Reports Fiscal 2025 First Quarter Results

06:30am, Wednesday, 05'th Feb 2025
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 first quarter ended December 31, 2024, revenue increased 12.8 percent year-over-year to $81.5 billio
Not for Distribution to U.S. Newswire Services for Dissemination in the United States VANCOUVER, BC / ACCESS Newswire / February 5, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) ("Cami
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Cencora (COR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qua
COR's fiscal first-quarter results are likely to reflect decent U.S. Healthcare Solutions segmental performance.
Rising patient volumes, technological advancements, rate hikes and other factors are likely to have benefited healthcare players during Q4. Companies like AMGN, COR, HUM and ARDT are likely to outperf
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. AXP, POOL, RJF and COR hold promise.
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Not for Distribution to U.S. Newswire Services for Dissemination in the United States VANCOUVER, BC / ACCESS Newswire / January 29, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) ("Cami
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the launch of its “Harrow Cares” program through a stra
Doximity, Omnicell, Embecta, Cencora and EDOC are included in this Analyst Blog.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE